Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc. (IMDX) Stock Overview

Explore Insight Molecular Diagnostics Inc.’s financial performance, market position, analyst ratings, and future outlook.

IMDX●NASDAQ
HealthcareMedical - Diagnostics & Research
$4.34
$0.04(0.93%)
U.S. Market opens in 58h 45m

Insight Molecular Diagnostics Inc. (IMDX)

Meyka AI Score

Z

Key Financials

Market Cap140.1M
P/E Ratio-2.90
EPS (TTM)$-1.49
ROE2.72%
Fundamental Analysis

AI Price Forecasts

1 Month$5.28
3 Months$8.61
1 Year Target$8.90

IMDX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Insight Molecular Diagnostics Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of IMDX on the NASDAQ shows an RSI of 44.32, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $8.90 for the NASDAQ listing.

Key metrics behind Insight Molecular Diagnostics Inc.'s NASDAQ-traded stock include a P/E ratio of -2.90 and a market capitalization of 140.1M. Combined with our AI analysis, these give both institutional and retail investors a clear view of IMDX on the NASDAQ.

Price Performance (NASDAQ: IMDX)

1-Day Change
0.93%
5-Day Change
15.43%
1-Month Change
-13.20%
3-Month Change
-26.19%
6-Month Change
-20.95%
Year-to-Date (YTD) Change
-42.13%
1-Year Change
75.00%
3-Year Change
24.00%
5-Year Change
-94.80%
All-Time (Max) Change
-97.31%

Contact Information

https://imdxinc.com
949 409 7600
2 International Plaza Dr., Nashville, TN, 37217

Company Facts

570 Employees
IPO DateDec 30, 2015
CountryUS
Actively Trading

Frequently Asked Questions